<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Head and Neck Tumors</journal-id><journal-title-group><journal-title xml:lang="en">Head and Neck Tumors</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли головы и шеи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-1468</issn><issn publication-format="electronic">2411-4634</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">6</article-id><article-id pub-id-type="doi">10.17650/2222-1468-2013-0-2-25-30</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ ГОЛОВЫ И ШЕИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">THE DIAGNOSIS AND TREATMENT OF MEDULLARY THYROID CANCER</article-title><trans-title-group xml:lang="ru"><trans-title>ДИАГНОСТИКА И ЛЕЧЕНИЕ МЕДУЛЛЯРНОГО РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Brzhezovsky</surname><given-names>V. Zh.</given-names></name><name xml:lang="ru"><surname>Бржезовский</surname><given-names>В. Ж.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>VBR1980@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Smirnova</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Смирнова</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kazubskaya</surname><given-names>T. P.</given-names></name><name xml:lang="ru"><surname>Казубская</surname><given-names>Т. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tkachev</surname><given-names>S. I.</given-names></name><name xml:lang="ru"><surname>Ткачев</surname><given-names>С. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow</institution></aff><aff><institution xml:lang="ru">Отделение опухолей черепно-челюстно-лицевой области НИИ клинической онкологии ФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow</institution></aff><aff><institution xml:lang="ru">НИИ клинической онкологии ФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2013</year></pub-date><volume>3</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>25</fpage><lpage>30</lpage><history><date date-type="received" iso-8601-date="2015-04-15"><day>15</day><month>04</month><year>2015</year></date><date date-type="accepted" iso-8601-date="2015-04-15"><day>15</day><month>04</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Brzhezovsky V.Z., Smirnova E.A., Kazubskaya T.P., Tkachev S.I.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, Бржезовский В.Ж., Смирнова Е.А., Казубская Т.П., Ткачев С.И.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Brzhezovsky V.Z., Smirnova E.A., Kazubskaya T.P., Tkachev S.I.</copyright-holder><copyright-holder xml:lang="ru">Бржезовский В.Ж., Смирнова Е.А., Казубская Т.П., Ткачев С.И.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ogsh.abvpress.ru/jour/article/view/6">https://ogsh.abvpress.ru/jour/article/view/6</self-uri><abstract xml:lang="en"><p>The paper presents many years’ international experience in treating medullary thyroid cancer (TC). Two hundred and forty-two patients with different stages of the disease were followed up. The morphological and genetic features of this tumor are given. The results of used treatment options for medullary cancer, such as surgical, radiation, multimodality, and drug therapies, are analyzed. Surgery is a leading treatment option for this disease. The volume of surgery on a primary tumor focus depends on both the shape of a (sporadic or hereditary) tumor and its sizes. Removal of pre- and paratracheal fat is indicated for any volume of surgery for TC due to the high risk of its metastases to lymph nodes at this site. For radiotherapy there are three main indications: 1) the dubious, macroscopically and microscopically evaluated efficiency of an operation; 2) inoperable cancer; 3) distant bone metastases for palliative and symptomatic care. The now chemicals available at an oncologist’s disposal exert no significant effect on increased survival in a patient with medullary TC.</p></abstract><trans-abstract xml:lang="ru"><p>В работе представлен многолетний опыт лечения медуллярного рака щитовидной железы (ЩЖ) (РЩЖ). Под наблюдением находилось 242 больных с различными стадиями заболевания. Приведены морфологические и генетические особенности этой опухоли. Проанализированы результаты применявшихся методов лечения медуллярного рака: хирургического, лучевого, комбинированного, лекарственного. В лечении этого заболевания ведущим методом является хирургический. Объем хирургического вмешательства на первичном опухолевом очаге зависит как от формы опухоли (спорадическая или наследственная), так и от ее размеров. При любом объеме операции на ЩЖ показано удаление пре- и паратрахеальной клетчатки в связи с высоким риском метастазирования в лимфатические узлы этой локализации. Для назначения лучевой терапии имеются 3 основных показания: 1) при сомнительной радикальности операции, оцененной как макроскопически, так и микроскопически; 2) при неоперабельных формах рака; 3) при отдаленных костных метастазах с паллиативной и симптоматической целью. Имеющиеся в арсенале онколога в настоящее время химиопрепараты не оказывают существенного влияния на увеличение продолжительности жизни больного медуллярным РЩЖ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>medullary cancer</kwd><kwd>thyroid</kwd><kwd>diagnosis</kwd><kwd>treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>медуллярный рак</kwd><kwd>щитовидная железа</kwd><kwd>диагностика</kwd><kwd>лечение</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Пачес А.И., Пропп Р.М. Рак щитовидной железы. М., 1995. 368 с.</mixed-citation><mixed-citation xml:lang="ru">Пачес А.И., Пропп Р.М. Рак щитовидной железы. М., 1995. 368 с.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Alsanea O., Clark O.H. Familial thyroid cancer. Curr Opin Oncol 2001 Jan;13(1):44–51.</mixed-citation><mixed-citation xml:lang="ru">Alsanea O., Clark O.H. Familial thyroid cancer. Curr Opin Oncol 2001 Jan;13(1):44–51.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Fuchshuber P.R., Loree T.R., Hicks W.L. Jr et al. Medullary carcinoma of the thyroid: prognostic factors and treatment recommendations. Ann Surg Oncol 1998 Jan–Feb;5(1):81–6.</mixed-citation><mixed-citation xml:lang="ru">Fuchshuber P.R., Loree T.R., Hicks W.L. Jr et al. Medullary carcinoma of the thyroid: prognostic factors and treatment recommendations. Ann Surg Oncol 1998 Jan–Feb;5(1):81–6.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Cupisti K., Simon D., Wolf A. et al. Surgical treatment of postoperative, incidentally diagnosed small sporadic C-cell carcinomas of the thyroid. Langenbecks Arch Surg 2000 Dec;385(8):526–30.</mixed-citation><mixed-citation xml:lang="ru">Cupisti K., Simon D., Wolf A. et al. Surgical treatment of postoperative, incidentally diagnosed small sporadic C-cell carcinomas of the thyroid. Langenbecks Arch Surg 2000 Dec;385(8):526–30.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Travagli J.-P., Gardet P., Blazquez D. et al. Traitement chirurgical du cancer medullaire de la thyroide. Bull Cancer (Paris) 1984;71(3):192–4.</mixed-citation><mixed-citation xml:lang="ru">Travagli J.-P., Gardet P., Blazquez D. et al. Traitement chirurgical du cancer medullaire de la thyroide. Bull Cancer (Paris) 1984;71(3):192–4.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Пачес А.И., Любаев В.Л., Шенталь В.В. и др. Современной состояние проблемы лечения рака щитовидной железы. Вопросы онкологии 1998;44(5):562–6.</mixed-citation><mixed-citation xml:lang="ru">Пачес А.И., Любаев В.Л., Шенталь В.В. и др. Современной состояние проблемы лечения рака щитовидной железы. Вопросы онкологии 1998;44(5):562–6.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Ellenhorn J.D., Shah J.P., Brennan M.F. Impact of therapeutic regional lymph node dissection for medullary carcinoma of thyroid gland. Surgery 1993 Dec;114(6):1078–81.</mixed-citation><mixed-citation xml:lang="ru">Ellenhorn J.D., Shah J.P., Brennan M.F. Impact of therapeutic regional lymph node dissection for medullary carcinoma of thyroid gland. Surgery 1993 Dec;114(6):1078–81.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Kebebew E., Clark O.H. Medullary thyroid cancer. Curr Treat Options Oncol 2000 Oct;1(4):359–67.</mixed-citation><mixed-citation xml:lang="ru">Kebebew E., Clark O.H. Medullary thyroid cancer. Curr Treat Options Oncol 2000 Oct;1(4):359–67.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Давыдов М.И., Матякин Е.Г., Шенталь В.В. и др. Хирургическое лечение опухолей верхней грудной апертуры. Вопросы онкологии 1999;45:301–5.</mixed-citation><mixed-citation xml:lang="ru">Давыдов М.И., Матякин Е.Г., Шенталь В.В. и др. Хирургическое лечение опухолей верхней грудной апертуры. Вопросы онкологии 1999;45:301–5.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Brierley J.D., Tsang R.W. External radiation therapy in the treatment of thyroid malignancy. Endocrinol Metab Clic North Am 1996 Mar;25(1):141–57.</mixed-citation><mixed-citation xml:lang="ru">Brierley J.D., Tsang R.W. External radiation therapy in the treatment of thyroid malignancy. Endocrinol Metab Clic North Am 1996 Mar;25(1):141–57.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Fersht N., Vini L., A’Hern R., Harmer C. The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. Thyroid 2001 Dec;11(12):1161–8. 12. Fife K.M., Bower M., Harmer C.L. Medullary thyroid cancer: the role of radiotherapy in local control. Eur J Surg Oncol 1996 Dec;22(6):588–91.</mixed-citation><mixed-citation xml:lang="ru">Fersht N., Vini L., A’Hern R., Harmer C. The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. Thyroid 2001 Dec;11(12):1161–8. 12. Fife K.M., Bower M., Harmer C.L. Medullary thyroid cancer: the role of radiotherapy in local control. Eur J Surg Oncol 1996 Dec;22(6):588–91.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">13. Droz J.P., Rougier P., Goddefroy V. et al. Chimiotherapie des cancers medullaires de la thyroide. Essais phase II avec adriamycine et cis-platinum administers en monochimiotherapie. Bull Cancer (Paris) 1984;71(3):195–9.</mixed-citation><mixed-citation xml:lang="ru">Droz J.P., Rougier P., Goddefroy V. et al. Chimiotherapie des cancers medullaires de la thyroide. Essais phase II avec adriamycine et cis-platinum administers en monochimiotherapie. Bull Cancer (Paris) 1984;71(3):195–9.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">14. Stein R., Chen S., Reed L. et al. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine. Cancer 2002 Jan 1;94(1):51–61.</mixed-citation><mixed-citation xml:lang="ru">Stein R., Chen S., Reed L. et al. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine. Cancer 2002 Jan 1;94(1):51–61.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
